Tetraphase Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2006-01-01
- Employees
- 67
- Market Cap
- -
- Website
- http://tphase.com
Clinical Trials
45
Active:29
Completed:16
Trial Phases
3 Phases
Phase 1:26
Phase 2:1
Phase 3:4
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (31 trials with phase data)• Click on a phase to view related trials
Phase 1
26 (83.9%)Phase 3
4 (12.9%)Phase 2
1 (3.2%)A Safety and PK Study of IV Eravacycline
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT03696550
- Locations
- 🇺🇸
Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States
Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Procedure: Bronchoalveolar lavage
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03691584
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03450187
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Phase 1 Safety and PK Study of IV TP-271
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03234738
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections
Phase 3
Completed
- Conditions
- Complicated Urinary Tract Infections
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 1205
- Registration Number
- NCT03032510
- Prev
- 1
- 2
- 3
- Next
News
No news found